pharma · Pancreatic Ductal Adenocarcinoma · Neuroendocrine Tumor Grade 2 · CATX
Perspective Therapeutics
Perspective Therapeutics is a pharma organization headquartered in Seattle, USA. It trades on NYSE under ticker CATX. Primary therapeutic focus areas include Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor Grade 2
Seattle, USA HQ
2023 Founded
144 Employees
Public company Type
CATX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2023
- Employees
- 144
- Programs
- 6
- Drugs
- 1
- Patents
- 1
[203Pb]VMT-α-NET
Phase 1 · small molecule · Neuroendocrine Tumor Grade 2
[203Pb]VMT-α-NET for Neuroendocrine Tumor Grade 2 is a Phase 1 program (small_molecule) at Perspective Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 202006288
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Perspective Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Neuroendocrine Tumor Grade 2
- Status
- active
- Trials
- 1